International Health Technology Publication Annual List Recognizes Innovation and Leaders in Health Technology Palo Alto, Calif., and London – January 29, 2020 – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, has been named to the 2020 Global Digital Health 100 list by The Journal of mHealth. Cognoa’s digital therapeutics will advance the standard of care by…
Cognoa CMO, Sharief Taraman, MD, DABPN, DABPM, FAAP, authored a MedCity News Influencer article about the potential of digital therapeutics and ai to empower pediatricians and make early intervention possible for more children. Our mental and behavioral health is largely determined by how the brain develops during the first few years of life when the brain is most actively developing.…
PALO ALTO, Calif.- January 6, 2020—Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that senior executives will be speaking at two healthcare innovation and investor conferences in San Francisco. ● Brent Vaughan, CEO and co-founder of Cognoa, will provide an update on the company’s milestones and strategy at the Digital Medicine & Medtech Showcase™ 2020,…
Palo Alto, Calif., December 18, 2019 – Cognoa, a company at the forefront of pediatric behavioral health, has won the Fierce Innovation Life Science Award for Technology Innovation. Cognoa’s digital therapeutics will advance the standard of care by giving every child the opportunity to receive treatments earlier when they can have the greatest impact. Currently, diagnosis and treatment of behavioral…
WRITTEN BY Shannon Ashley The American Academy of Pediatrics (AAP) recommends that all children get screened for autism spectrum disorder at their 18- and 24-month well-child checkups. Today, those recommendations have been significantly enhanced. These new guidelines now recommend developmental and behavioral surveillance at 9-, 18-, and 30-month visits in addition to the standardized ASD screening at 18 and 24 months old.…
Currently, most pediatricians choose to refer children to a specialist to be diagnosed and treated for behavioral conditions such as autism — often with waitlists of a year to three years. Nationwide, we continue to face an enormous and growing shortage of specialists, so the heartbreaking reality for most children and families is delayed diagnosis and late access to treatments.…
Cognoa develops AI-powered digital therapeutics and medicines that advance the standard of care in pediatric behavioral health and improve lifelong outcomes for children Palo Alto, Calif., December 5, 2019 – Cognoa, a company at the forefront of pediatric behavioral health, announced today that it has been selected as a finalist in Questex’s Fierce Innovation Awards – LifeSciences Edition 2019, a…
James Welch brings two decades experience scaling high-growth companies to Cognoa as company prepares for commercialization PALO ALTO, Calif.– December 2, 2019 –Cognoa, a company at the forefront of pediatric behavioral health, announced today that James (Jim) H. Welch has been appointed Chief Financial Officer. Welch will oversee financial planning, operations and investor relations as the company advances its digital…
Cognoa launches a pivotal study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). Read article here.
Palo Alto, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of pediatric behavioral health, announced today initiation of its Pivotal Study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). The company anticipates submitting the results of this multi-site, prospective, blinded, active comparator study to the U.S. Food and Drug Administration (FDA)…
